Valiant Laboratories Ltd.
131.05
INR
-2.67
(-2.00%)
ISIN
INE0JWS01017
Return %
Stock
S&P 500
1Y
58.06
14.20
3Y
-25.39
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Santosh Shantilal Vora
- Full Time Employees
- 84
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 701, Tower B Mumbai MA India 400083
- IPO Date
- Oct 6, 2023
- Website
- valiantlabs.in
- Similar Companies
- Business
- Valiant Laboratories Limited operates as an active pharmaceutical ingredient (API) and bulk drug manufacturing company primarily focused on the production of paracetamol in various grades, including Indian Pharmacopoeia (IP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopoeia (USP) standards. The company manufactures paracetamol used widely in treatments for headaches, muscle aches, arthritis, backaches, toothaches, cold, and fever. Additionally, it offers specialty chemicals and has a research and development facility equipped with analytical laboratories for developmental activities related to existing products. Its manufacturing unit, located in Palghar, Maharashtra, India, has an annual installed capacity of 9,000 metric tons. Founded in 1980 and headquartered in Mumbai, Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP and serves markets both in India and internationally. Recent strategic developments include investment in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL), for financing capital expenditure related to the establishment of a specialty chemicals manufacturing facility at Saykha Industrial Area, Bharuch, Gujarat. This expansion aims to diversify the company’s product portfolio into specialty chemical segments such as ketene and diketene derivatives. Valiant Laboratories has also provided funding to VASPL for working capital requirements. The company underwent a name change from Bharat Chemicals to Valiant Laboratories Limited in August 2021 and has seen significant sales growth and profitability improvement throughout 2024 and 2025, marking a turnaround from prior losses. The company’s core business segments include pharmaceutical ingredients—mainly paracetamol—and specialty chemicals. It primarily targets pharmaceutical formulation companies as customers requiring high-grade bulk drug material and specialty chemicals. Valiant Laboratories also actively invests in R&D to enhance product quality and develop specialty chemicals. It is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE), reflecting its established position within the pharmaceutical preparations industry in India. Valiant Laboratories’ operational footprint centers in India, with a manufacturing base in Maharashtra and an upcoming facility in Gujarat, supporting both domestic supply chains and international exports. The company’s financial and operational disclosures indicate sustained efforts to expand capacity, improve profitability, and strengthen its specialty chemicals segment in line with evolving industry demands. This profile captures Valiant Laboratories Limited as a specialized pharmaceutical ingredient manufacturer with a strong focus on paracetamol production, emerging diversification into specialty chemicals, recent capital investments in a subsidiary for facility expansion, and improving financial performance post-2023.